Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03708367
Recruitment Status : Recruiting
First Posted : October 17, 2018
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Surgical Vision, Inc.

Brief Summary:
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative LipiFlow treatment. Three months postoperatively, both groups will be evaluated for clinical outcomes and the Control group will receive LipiFlow treatment as the cross-over group. The Control group will be evaluated at 4 months postoperative for clinical outcomes.

Condition or disease Intervention/treatment Phase
Cataracts Meibomian Gland Dysfunction (MGD) Device: LipiFlow Thermal Pulsation System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
Actual Study Start Date : October 16, 2018
Estimated Primary Completion Date : August 31, 2019
Estimated Study Completion Date : August 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Study Group: LipiFlow Treatment at PreOp
Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
Device: LipiFlow Thermal Pulsation System
Treatment at preoperative visit for study group

Control Group
Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
Device: LipiFlow Thermal Pulsation System
Treatment at 3 month visit as the cross-over group




Primary Outcome Measures :
  1. Uncorrected Distance Visual Acuity (UCDVA) [ Time Frame: 10 to 14 weeks postoperative ]
    Mean monocular UCDVA at 3 months postoperative in the Study and Control groups.

  2. Rate of Refractive Predictability [ Time Frame: 10 to 14 weeks postoperative ]
    Rate of refractive predictability (i.e., within 0.50 D of target refraction, and within 1.00 D of target refraction) at 3 months postoperative.

  3. Rate of Bothersome Ocular Symptoms [ Time Frame: 10 to 14 weeks preoperative ]
    Rate of directed bothersome ocular symptoms at 3 months postoperative.

  4. Total Meibomian Gland Score [ Time Frame: 30 to 60 days postoperative ]
    Mean change in total meibomian gland score from Baseline to the 1-month (30 to 60 days) postoperative visit.

  5. Precision of Preoperative Axial Length [ Time Frame: 0 to 8 weeks preoperative ]
    Precision (standard deviation) of preoperative axial length (AL).

  6. Precision of Preoperative Anterior Chamber Depth [ Time Frame: 0 to 8 weeks preoperative ]
    Precision (standard deviation) of anterior chamber depth (ACD).

  7. Precision of Keratometric Measurements [ Time Frame: 0 to 8 weeks preoperative ]
    Precision (standard deviation) of keratometric measurements (K).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (all criteria apply to each study eye):

  • Minimum 22 years of age.
  • Bilateral cataracts for which phacoemulsification extraction and implantation with Symfony IOLs have been planned.
  • Evidence of Meibomian Gland Dysfunction (MGD) in both eyes based on assessment of meibomian glands of the lower eyelid
  • None to moderate dry eye symptoms with questionnaire
  • Clear intraocular media other than cataract in each eye.
  • Availability, willingness, ability and sufficient cognitive awareness to comply with the study protocol including: randomization; examination procedures; completion of planned bilateral cataract surgeries; compliance with no use of other MGD or dry eye treatments.
  • Ability to understand, read and write English to consent to study participation and complete study questionnaires.
  • Willingness to sign informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing country.

Exclusion Criteria (all criteria apply to each study eye):

  • Any medical finding that would predictably result in a postoperative best corrected distance visual acuity worse than 20/30 in either eye.
  • Use of systemic or ocular medications that, in the opinion of the investigator, may affect vision or impact pupil dilation or iris structure.
  • Irregular corneal astigmatism.
  • Any clinically-significant corneal pathology / abnormality other than regular corneal astigmatism.
  • Any clinically-significant pupil abnormalities.
  • Subjects with conditions associated with increased risk of zonular rupture.
  • Unwillingness or inability to stop wearing contact lens at least two weeks prior to the baseline visit.
  • Known ocular disease or pathology that, in the opinion of the investigator, may affect visual acuity or require surgical intervention during the study.
  • Systemic disease condition that causes dry eye.
  • Unwillingness or inability to abstain from the use of systemic medications known to cause dryness for the study duration. Subjects must have discontinued these medications for at least 1 month prior to Preoperative Visit.
  • Unwillingness or inability to abstain from the use of systemic antihistamines.
  • Unwillingness or inability to abstain from use of prescription medications for treatment of MGD or dry eye. Subject must have dicontinued using prescription medications for MGD or dry eye at least 1 month prior to baseline preoperative visit #1 measurements.
  • Any of the following ocular (eye or eyelid) conditions in either eye within 3 months prior to the LipiFlow treatment visit:

    • Prior intraocular, oculoplastic, corneal or refractive surgery procedure (LASIK, LASEK, RK, PRK, etc.).
    • Ocular trauma.
    • Ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.
    • History of recurrent ocular inflammation.
    • Punctal plug insertion or punctal occlusion.
  • Any of the following active ocular (eye or eyelid) conditions in either eye at the baseline Preoperative Visit #1 measurements:

    • Ocular infection.
    • Ocular inflammation.
    • Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis
    • Severe (Grade 3 or 4) inflammation of the eyelid.
    • Eyelid abnormalities that affect lid function.
    • Ocular surface abnormality that may compromise corneal integrity.
  • Concurrent participation or participation within 30 days prior to study visit in any other clinical trial.
  • Planned monovision correction.
  • Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03708367


Contacts
Layout table for location contacts
Contact: Leilei Ji 408-273-4100 lji4@its.jnj.com

Locations
Layout table for location information
United States, California
Empire Eye & Laser Center, Inc. Recruiting
Bakersfield, California, United States, 93309
United States, Texas
JW Eye Associates, P.A. Recruiting
Dallas, Texas, United States, 75243
Texas Eye & Laser Center, P.A. Recruiting
Hurst, Texas, United States, 76054
Sponsors and Collaborators
Johnson & Johnson Surgical Vision, Inc.
Investigators
Layout table for investigator information
Study Director: Priya Janakiraman, OD Johnson & Johnson Surgical Vision, Inc.

Layout table for additonal information
Responsible Party: Johnson & Johnson Surgical Vision, Inc.
ClinicalTrials.gov Identifier: NCT03708367     History of Changes
Other Study ID Numbers: DRYE-102-SELF
First Posted: October 17, 2018    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Lens Diseases
Eye Diseases